Slingshot Insights is the first crowdfunded expert network and due diligence community. Members use our suite of tools to cut through the noise and Become the Smart Money. We provide you affordable access to Experts and Management Teams so that you can make informed investment decisions. By grouping investors around project ideas they care about, we pass along significant savings without compromising on quality.
Strong Bio is a growth-focused analyst seeking identification of unique investment opportunities in biotechnology that arise as high probability market niche innovation or expansion based on scientific peer-reviewed evidence supportive of novel mechanism(s) of action. By diligently screening investment candidates in multiple biotechnology sectors, initial position recommendations and reinforcing position pricing profiles can be systematically evaluated citing fundamental trends for investors to exploit. If you would like to request that Strong Bio publish an article on a company of interest, please request by private message. Strong Bio reminds the reader that investment in biotechnology can be considered high risk, and diversification of assets is a necessity.
Investor/trader focused on discovering under the radar stocks and alpha generating ideas for my readers. Additionally, I try to give a differentiated take on names readers might already be familiar with. My specialty is looking specifically for opportunities to achieve high % gains within a year's timeframe (ROTY- Runners of the Year). Last but not least, I highlight risk management and entry/exit strategies quite a bit, as I believe they represent areas that are often neglected but materially important for readers to understand and apply.
TipRanks Top 150 First Half 2017 (Top 100 First Quarter)
My biggest successes have been in the biotech arena (over $300k personal portfolio profits), while my biggest losses have been due to overconfidence and a failure to adequately heed the bear thesis on my picks.
As always, all posts are my personal opinion. None of my material should be considered as investment advice, as readers must make their own decisions based on their own financial situations or are encouraged to utilize an investment professional (CFP, etc). Trading and investing in stocks can be very risky, and investors can lose up to 100% of principal in the event of adverse circumstances. By reading my material readers are agreeing to the above and assuming all responsibility for their own investment decisions.
FAQ (Frequently Asked Questions)
1: Why don't you have positions in each of the ROTY model account ideas?
It's a great question, one I've been getting recently and good for those who have asked it. Long story short, I've cashed out the majority of my portfolio, including gains from previous years, to buy a condo here in Peru, the kind I've always wanted but never thought I'd be able to afford. I'm very thankful for where trading and investing has taken me up to this point. I also used the funds with my wife to start her retail clothing chain, one which has a unique premise and wide moat. After we finish furnishing the place as well as get her business into a dominant self-sustaining position, I plan to turn future cashflow toward ROTY investing. The scalable ROTY model account is a transparent manner for me to show readers in real-time how I would be going about my trades in hopes that they find it useful, regardless of their account size.
2: What should I do if a binary catalyst or key event is coming for a stock that I own?
Again, I don't give advice, but what I would do personally depends on the situation. In general we try to purchase stocks months or even over a year out before such an event happens, so that we can "play the runup". If for example a stock rises 50% prior to the event, an investor can take full profits (sell the position) before the event if he or she has low risk tolerance (ie. doesn't want to lose money). If the investor has higher risk tolerance (I'm in this category generally), he or she can take partial profits (ie. sell 25% to 75% of shares) and hold the rest. If the trial data is positive or treatment is approved by the FDA or earnings are outstanding, then the investor will enjoy that big gain and bank the money. However, if the event has a disappointing result, at least you've already locked in gains and lose less. Just my two cents and how I typically operate.
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Over 35 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action; and biotech. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
Derek Getz is an individual investor seeking to navigate the investment world in order to provide a wealthy and stable retirement for his family. His aim is to help fellow investors, notably younger investors, establish a plan to produce a growing stream of income. Derek holds a Bachelor's degree in Computer Science with a minor in Economics from the University of Delaware and lives with his wife and two children.
Derek created and runs customstockalerts.com. It's a utility for investors to stay on top of all their stocks. Pick a company you are interested in, pick an alert type (price, dividend yield, PE, etc) and a value. You'll get a text or email (your choice) when your value hits.
There is also an ex-dividend utility, sending alerts when your companies are getting close to the big day. Use it as a chance to buy and collect the dividend!
Come check me out at customstockalerts.com and dividendderek.com!
Master in Physics and Mathematics at Free University Amsterdam (1987). Using physics and mathematics to invest in stock markets. Started my investment research activities since 1996, mainly in technology stock. Developing a complex technical analysis model with predictive component on price. Model IndexClues is based upon complex polynomials (fractal / chaos theory) and applies to stock markets, stock market indices, commodities and currencies.
My Dividends Forever! Portfolio is comprised of companies that I believe will continue to reward investors with dividend increases for years to come. I never intend to sell a stock in my Dividends Forever! Portfolio unless my original investing thesis changes. I also invest in growth stocks that I think will deliver outstanding returns over the years. SeekingAlpha is a great platform that allows investors to share their knowledge and discuss investing strategies. Hit the follow tab to keep up on my latest articles!
Quad 7 Capital, parent company of Quad 7 Research and Quad 7 Poker, was founded in 2017 by a long time investor, Seeking Alpha author, professor and politician. The company has expertise in policy, economics, mathematics, game theory and the sciences. The company has experience with government, academia, and private industry. Quad7Capital.com covers a wide range of sectors and companies, with particular emphasis on growth companies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies. It further offers money saving tips and market news. Quad 7 Partners focuses on current events, earnings, and timely developments. Quad 7 Research aims to conduct 2-3 analyses per business day in addition to working with clientele, personal portfolio advisement and conduct freelance research
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
The Clinically Sound Investor is a pharmacist with a PharmD and a BA in psychology. He has worked across the spectrum from very small independent and hospital pharmacies to the some of the largest retail corporations and medical centers in the nation, as well as experience in specialty and mail order settings. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results. His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
Aviate Global is in the ideas business
- Our ideas will make money for clients, or will make them think.
Aviate Global is distinctive:
- Where others seek to ‘...cover the market…’ with massed ranks of analysts, Aviate Global has a small number of experts focused on compelling alpha-generating ideas.
Our process is based on our belief that big money is made from big ideas:
- We identify and understand catalysts for change
- We filter market noise and search for the stock that is most relevant to the identified change
- We produce high-quality substantive, intellectually rigorous research
Our global boutique model ensures our work in London, New York , Hong Kong Sydney is aligned to the process
Anita Dushyanth is a Biotechnology Technology and Medical Devices Analyst with Zacks Investment Research.
She has worked as a researcher in the field of Bioengineering at the University of California, Los Angeles (UCLA) for over 10 years. Her expertise includes research that delves into the biomechanics of the human body, degenerative disease progression, quantitative image analysis and optimization, and design and development of medical compliant devices. She has published and presented several research articles and has also been a peer reviewer and an editor for a number of prestigious journals in the field of biomedical engineering. Prior to that, Anita worked as a researcher at the Department of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF).
Anita holds a PhD degree in Bioengineering from UCLA, M.S. in Biomedical Engineering from Wright State University, Dayton, OH and B.S. in Instrumentation Engineering from the University of Madras, India.
Bay Area Biotech is a group of self-organized life science graduate/medical/business students and postdoctoral scholars who are interested in utilizing our scientific training to evaluate biotechnologies and identify investment opportunities. Opinions published here are those of the authors.
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012.
ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.
Visit: ChinaBio Today (http://www.chinabiotoday.com)
ChinaBio LLC (http://www.chinabiollc.com)
Patrick Young is an independent investor. He previously worked in Upstream R&D for ExxonMobil. He has a M.S. in Geology focused on igneous petrology and geochemistry, and is currently working towards a Ph.D. in the same at Yale University. He has wide interests in technology, particularly energy infrastructure.
Innovalpha Sàrl is an independent company founded in March 2010 based in Geneva, Switzerland. The author is the originator of the IP models and founder of the company. He has more than ten years of experience in the Intellectual Property field as Patent Search Specialist and Patent Attorney. He is actually working as Legal Counsel and Intellectual Property Director for a small Healthcare company.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
"Amateur's practice till they get it right, experts practice till they can't get it wrong"
I am an amateur investor who, retired at 37 to trade stocks for a living. Prior to that I have worked in EMS, and Respiratory Therapy. The foundation of my investments are always that someone else gave me the suggestion, and I did the research. I hope you will follow my example and do your own research on any stock I recommend.
I am currently a Junior at the George Washington University and have been investing since the sixth grade with my own money. I am very interested in the pharmaceutical sectors, but will buy just about any stock if I feel that the company is undervalued. I hope to provide some helpful insight, and to in turn learn a lot from the rest of the investment community.
I have 20+ years of experience in biotech investments. I am a chemical engineer and hold a Ph.D. in microbial physiology, but I am not an MD. I have authored or co-authored more than 20 peer reviewed scientific papers.
Long/short biotech investment ideas with a focus on oncology/infectious disease/immunology.
Articles on this site are my own and do not represent the positions, strategies, or opinions of my employer.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
A researcher into gene silencing as a technology for improving the lives of those suffering from incurable diseases. Benitec Biopharma is my primary investment in this technology as ddRNAi offers one-time treatments for a broad range of these diseases.
I'm a self-directed investor who shares my experience in investing. I read, learn, and apply every day.
I write about value, dividend, and growth investing from the perspective of a Canadian. I invest in individual stocks on the US stock exchanges and the Toronto Stock Exchange.
As I write, I reflect on my own actions and results, which is an amazing exercise. I encourage individual investors who enjoy writing to try it.
I appreciate the work done by SA staff & authors and love the SA community that engages in meaningful discussions.